Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8667623 | Journal of Cardiac Failure | 2018 | 31 Pages |
Abstract
In HFpEF and especially HFmrEF, NT-proBNP was more prognostic and discriminatory, but also more affected by confounders such as AF. These data support the use of NT-proBNP for eligibility, enrichment, and surrogate end points in HFpEF and HFmrEF trials, and suggest that cutoff levels for eligibility should be carefully tailored to comorbidity.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Gianluigi MD, PhD, Nicola PhD, Camilla PhD, Ulf MD, PhD, Ola MD, PhD, Giuseppe M.C. MD, PhD, Lars H. MD, PhD,